Risk factors for severe infection and rationale for immunoglobulin monitoring during rituximab treatment in autoimmune rheumatic diseases

Md Yusof, MY orcid.org/0000-0003-3131-9121, Vital, EM orcid.org/0000-0003-1637-4755, McElvenny, D et al. (5 more authors) (2017) Risk factors for severe infection and rationale for immunoglobulin monitoring during rituximab treatment in autoimmune rheumatic diseases. In: Annals of the Rheumatic Diseases. Annual European Congress of Rheumatology (EULAR 2017), 14-17 Jun 2017, Madrid, Spain. Vol. 76 (Suppl 2). BMJ Publishing Group, p. 987. ISSN: 0003-4967. EISSN: 1468-2060.